172 related articles for article (PubMed ID: 22081459)
1. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
Hosein PJ; Craig MD; Tallman MS; Boccia RV; Hamilton BL; Lewis JJ; Lossos IS
Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459
[No Abstract] [Full Text] [Related]
2. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
Ogura M; Kim WS; Uchida T; Uike N; Suehiro Y; Ishizawa K; Nagai H; Nagahama F; Sonehara Y; Tobinai K
Jpn J Clin Oncol; 2021 Feb; 51(2):218-227. PubMed ID: 33051668
[TBL] [Abstract][Full Text] [Related]
3. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA
Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972.
Rybak ME; Anderson JR; Poulin RF; Amrein PC; Canellos GP; Gottlieb AJ
Cancer Treat Rep; 1986 Oct; 70(10):1233-4. PubMed ID: 3530451
[No Abstract] [Full Text] [Related]
9. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
10. [Our experience in the treatment of Hodgkin's disease and other reticulopathies with Ro4-6467 (Natulan)].
Arroyo de la Fuente F; Lasheras Garde J; Triginer Boixeda J
Sangre (Barc); 1966; 11(3):265-70. PubMed ID: 6012465
[No Abstract] [Full Text] [Related]
11. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
12. [Multiple drug therapy in Hodgkin's disease, lymphosarcoma and reticulosarcoma].
Con I; Daiber A; Donoso A; Osorio G; Mora F
Rev Med Chil; 1972 Apr; 100(4):408-13. PubMed ID: 4557485
[No Abstract] [Full Text] [Related]
13. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
[TBL] [Abstract][Full Text] [Related]
14. [A new methylhydrazine derivative (Ro 4-6467 or Natulan) in the treatment of Hodgkin's disease. Study of 10 cases].
da Silva MP; Kerbauy J; de Guerra CC
Rev Bras Med; 1966 Jul; 23(7):483-9. PubMed ID: 6014416
[No Abstract] [Full Text] [Related]
15. Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial.
Coutinho F; Manhani AR; Velasquez WS; Del Giglio A
Acta Haematol; 2004; 112(3):121-5. PubMed ID: 15345892
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
17. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
19. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.
Rothe A; Schulz H; Elter T; Engert A; Reiser M
Haematologica; 2004 Jul; 89(7):875-6. PubMed ID: 15257947
[TBL] [Abstract][Full Text] [Related]
20. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]